Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction

James D. Richardson, Angela G. Bertaso, Peter J. Psaltis, Lachlan Frost, Angelo Carbone, Sharon Paton, Adam J. Nelson, Dennis T. L. Wong, Matthew I. Worthley, Stan Gronthos, Andrew C. W. Zannettino, Stephen G. Worthley

Research output: Contribution to journalArticleResearchpeer-review

42 Citations (Scopus)


Background: Although mesenchymal stem/stromal cells (MSC) have shown therapeutic promise after myocardial infarction (MI), the impact of cell dose and timing of intervention remains uncertain. We compared immediate and deferred administration of 2 doses of MSC in a rat model of MI. 

Methods and Results: Sprague-Dawley rats were used. Allogeneic prospectively isolated MSC ("low" dose 1 × 106 or "high" dose 2 × 106 cells) were delivered by transepicardial injection immediately after MI ("early-low," "early-high"), or 1 week later ("late-low," "late-high"). Control subjects received cryopreservant solution alone. Left ventricular dimensions and ejection fraction (EF) were assessed by cardiac magnetic resonance. All 4 MSC-treatment cohorts demonstrated higher EF than control animals 4 weeks after MI (P values <.01 to <.0001), with function most preserved in the early-high group (absolute reduction in EF from baseline: control 39.1 ± 1.7%, early-low 26.5 ± 3.2%, early-high 7.9 ± 2.6%, late-low 19.6 ± 3.5%, late-high 17.9 ± 4.0%). Cell treatment also attenuated left ventricular dilatation and fibrosis and augmented left ventricular mass, systolic wall thickening (SWT), and microvascular density. Although early intervention selectively increased SWT and vascular density in the infarct territory, delayed treatment caused greater benefit in remote (noninfarct) myocardium. All outcomes demonstrated dose dependence for early MSC treatment, but not for later cell administration. 

Conclusions: The nature and magnitude of benefit from MSC after acute MI is strongly influenced by timing of cell delivery, with dose dependence most evident for early intervention. These novel insights have potential implications for cell therapy after MI in human patients.

Original languageEnglish
Pages (from-to)342-353
Number of pages12
JournalJournal of Cardiac Failure
Issue number5
Publication statusPublished - May 2013
Externally publishedYes


  • cardiac magnetic resonance
  • hypoxic conditioning
  • Mesenchymal stem cells
  • myocardial infarction
  • optimisation
  • prospective isolation
  • repair
  • timing

Cite this